Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-titration study of (+)-α-dihydrotetrabenazine for tardive dyskinesia
2022-000271-39Phase 2Active
- Sponsor
- Adeptio Pharmaceuticals
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of (+)-α-dihydrotetrabenazine in tardive dyskinesia (TD), sponsored by Adeptio Pharmaceuticals. Primary endpoint: AIMS Dyskinesia Total Score change at week 8. Started Sep 2022; status: active.
02
Drugs
(+)-α-dihydrotetrabenazine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on 2022-000271-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000271-39.